Gilead Sciences, Inc.

GILD

US3755581036

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Employees

18,000

Sector

Pharmaceuticals

Calendar

2024-12-12 - Détachement de

More about the company

Income Statement and Estimates

income-statement-evolution-chart GILEAD-SCIENCES-INC

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

92.34USD

Average target price

98.34USD

Spread / Average Target

+6.50%

Consensus

Profit revisions

estimates-change-chart GILEAD-SCIENCES-INC

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart GILEAD-SCIENCES-INC

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-10 pm EST			5-day change	1st Jan Change
92.34 ^USD	+1.93%		-0.16%	+13.99%

Dec. 10	Gilead Sciences, Arcellx's CAR-T Therapy Supports 2030 Oncology Ambitions, Oppenheimer Says	MT
Dec. 10	Oppenheimer Adjusts Price Target on Gilead Sciences to $115 From $105, Maintains Overweight Rating	MT

Gilead Sciences, Arcellx's CAR-T Therapy Supports 2030 Oncology Ambitions, Oppenheimer Says	Dec. 10	MT
Oppenheimer Adjusts Price Target on Gilead Sciences to $115 From $105, Maintains Overweight Rating	Dec. 10	MT
Oppenheimer Adjusts Price Target on Gilead Sciences to $115 From $105, Keeps Outperform Rating	Dec. 10	MT
Gilead Sciences Unit Says Followup Data Support 'Durable' Efficacy of Tecartus CAR T-Cell Therapy	Dec. 09	MT
Kite, Gilead Company, Announces Results from Five-Year Follow-Up Analysis of ZUMA-5, Phase 2 Study of Yescarta in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas Including Follicular Lymphoma or Marginal Zone Lymphoma	Dec. 09	CI
Kite, Gilead Company, Announces Results from Four Analyses That Continue to Demonstrate Durability of Response of Tecartus in Patients with R/R MCL and R/R B-ALL During 66th ASH Annual Meeting and Exposition	Dec. 09	CI
Gilead Sciences, Inc.' Company Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASH	Dec. 08	CI
Gilead Sciences Seeks Small Acquisitions	Dec. 04	CI
Gilead Sciences, Inc. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-04-2024 11:40 AM	Dec. 04
HSBC Adjusts Price Target on Gilead Sciences to $82 From $69	Dec. 04	MT
Gilead Sciences Insider Sold Shares Worth $23,065,271, According to a Recent SEC Filing	Dec. 03	MT
Gilead Sciences, Inc. Presents at Piper Sandler 36th Annual Healthcare Conference, Dec-03-2024 11:00 AM	Dec. 03
Gilead Sciences Partners With Tubulis on Antibody-Drug Conjugate Development for Solid Tumors	Dec. 03	MT
Gilead Sciences, Inc. and Tubulis Enter into Exclusive Option and License Agreement to Discover and Develop Antibody-Drug Conjugate Against Solid Tumor Target	Dec. 03	CI
European Commission Secures 2.3 Million Doses of Gilead's COVID-19 Drug	Dec. 02	MT
Jefferies Raises Price Target on Gilead Sciences to $115 From $105	Dec. 02	MT
Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 Results	Nov. 27	CI
UBS Raises Price Target on Gilead Sciences to $96 From $70, Maintains Neutral Rating	Nov. 22	MT
Mizuho Securities Adjusts Price Target on Gilead Sciences to $100 From $90	Nov. 20	MT
Gilead Sciences, Inc. Presents at Jefferies London Healthcare Conference 2024, Nov-20-2024 09:30 AM	Nov. 20
Daiwa Securities Adjusts Gilead Sciences Price Target to $90 From $73	Nov. 18	MT
RBC Capital Adjusts Gilead Sciences Price Target to $84 From $81	Nov. 18	MT
IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer	Nov. 18	CI
Gilead Sciences Says Most of Phase 3 Primary Biliary Cholangitis Participants Treated With Livdelzi Achieved Biochemical Response	Nov. 15	MT
Gilead's Livdelzi Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis	Nov. 15	CI

Gilead Sciences, Inc.

Equities